Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway
T-lymphocytes have the potential to recognize cancer antigens as foreign and therefore eliminate them. However, immune checkpoints such as cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and programmed cell death (PD)-1 receptor and its ligands (PD-L1, PD-L2) suppress the activity of T-lymphocyte...
Main Authors: | Momtaz, Parisa, Postow, Michael A |
---|---|
Format: | Online |
Language: | English |
Published: |
Dove Medical Press
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238865/ |
Similar Items
-
Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction
by: Hendriks, Djoke, et al.
Published: (2016) -
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
by: Callahan, Margaret K., et al.
Published: (2015) -
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
by: O’Donnell, Jake S., et al.
Published: (2016) -
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
by: Ma, Weijie, et al.
Published: (2016) -
Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer
by: Dhodapkar, Kavita, et al.
Published: (2014)